Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial

Martin, Paul; Feltbower, Richard; Brown, Julia; Mason, Su; Mason, James; Nathan, J.; Richards, ID Gerald; Dowell, Anthony; Axon, Anthony

doi:10.1016/s0140-6736(00)02236-4

Cited by 164 publications

(147 citation statements)

References 22 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…58,59 Lower compliance did not affect overall cost-effectiveness, though absolute gains fall because screening is a 'one-off' event and compliance is likely to have a simple linear relationship with the number of deaths prevented. Those who fail to turn up for screening and treatment give rise to few costs.…”

Section: Discussionmentioning

confidence: 98%

“…The question of whether H. pylori eradication can increase the incidence of oesophagitis has been debated, 78 but recent randomised controlled trials (RCTs) of H. pylori eradication have not demonstrated any increase in such symptoms. 59 Nevertheless, the impact of widespread eradication of infection on the efficacy of PPIs in gastro-oesophageal reflux disease is unknown. Furthermore there are no good data to support the suggestion of an increase in incidence of oesophageal cancer after eradication of H. pylori.…”

Section: Discussionmentioning

confidence: 99%

“…Levels of screening uptake and compliance were set higher than those given in recent primary care studies of H. pylori screening, 58,59 on the basis that these studies were not set up to prevent gastric cancer or peptic ulcer.…”

Section: Compliancementioning

confidence: 99%

See 2 more Smart Citations

The cost-effectiveness of screening for Helicobacter pylori to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model

Roderick

Davies

Raftery

et al. 2003

Health Technol Assess

113

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK.We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTAThe cost-effectiveness of screening for Helicobacter pylori to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model P Roderick NHS R&D HTA ProgrammeT he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS.Initially, six HTA panels (pharmaceuticals, acute sector, primary and community care, diagnostics and imaging, population screening, methodology) helped to set the research priorities for the HTA Programme. However, during the past few years there have been a number of changes in and around NHS R&D, such as the establishment of the National Institute for Clinical Excellence (NICE) and the creation of three new research programmes: Service Delivery and Organisation (SDO); New and Emerging Applications of Technology (NEAT); and the Methodology Programme.This has meant that the HTA panels can now focus more explicitly on health technologies ('health technologies' are broadly defined to include all interventions used to prom...

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The cost-effectiveness of screening for Helicobacter pylori to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model

Roderick

Davies

Raftery

et al. 2003

Health Technol Assess

113

View full text Add to dashboard Cite

show abstract

“…2 The incidence of symptomatic or endoscopic GERD developing in ulcer patients cured of the infection, however, has ranged widely in other reports. [3][4][5][6][7] The results of H. pylori eradication in non-ulcer dyspepsia have been mixed, with some studies showing no benefit and others demonstrating improvement in symptoms and prevention of future ulcer disease. [8][9][10] A recent meta-analysis demonstrated modest efficacy for H. pylori eradication in alleviating dyspeptic symptoms with a number needed to treat of 19. 11 A subsequent meta-analysis using individual patient data suggested that the benefit of eradication was similar whether patients with predominant epigastric pain or predominant heartburn were studied.…”

Section: Introductionmentioning

confidence: 99%

Patterns of gastritis and the effect of eradicating Helicobacter pylori on gastro‐oesophageal reflux disease in Western patients with non‐ulcer dyspepsia

Vakil

Talley

Stolte

et al. 2006

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…In the United Kingdom, Moayyedi et al found that dyspepsia-related expenditures declined after H. pylori was eradicated and that the savings were greater than the initial cost of a 'test and treat' strategy [Moayyedi et al 2000]. Lane et al also confirmed that the 'test and treat' strategy could reduce the costs associated with dyspepsia by 30% at two years after eradication [Lane et al 2006].…”

Section: Introductionmentioning

confidence: 99%

Review: Eradication of Helicobacter pylori to prevent gastroduodenal diseases: Hitting more than one bird with the same stone

Lee

Liou

et al. 2008

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Abstract:Helicobacter pylori (H. pylori ) are gram-negative bacteria that selectively colonizes the gastric mucosa. The prevalence of H. pylori infection varies from 20 to 50% in industrialized countries to over 80% in developing countries. The infection may persist lifelong without specific treatment. Prolonged infection and inflammation due to bacterial virulence and host genetic factors will lead to chronic gastritis. A certain portion of infected patients then develop more severe pathologies such as peptic ulcer (10-15%), gastric cancer (1%), and mucosaassociated lymphoid tissue lymphoma (50.01%). Although the majority of infected patients remain asymptomatic, much of the evidence has shown that eradication of H. pylori infection can reduce the recurrence of peptic ulcer and benefit a substantial portion of patients with nonulcer dyspepsia. Though controversial in population-based clinical trials, several cost-effectiveness analyses also reveal that H. pylori eradication is cost effective in the primary prevention of gastric cancer. Therefore, the discovery of H. pylori offers the chance to prevent several gastroduodenal diseases by means of their eradication. In other words, gastroenterologists could hit more than one bird with one stone. However, there are concerns regarding application of a 'test and treat' strategy in the general population. In this review, we will focus on current evidence of H. pylori eradication in the primary and secondary prophylaxis of gastric cancer and peptic ulcer disease.

show abstract

Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial

Cited by 164 publications

References 22 publications

The cost-effectiveness of screening for Helicobacter pylori to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model

The cost-effectiveness of screening for Helicobacter pylori to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model

Patterns of gastritis and the effect of eradicating Helicobacter pylori on gastro‐oesophageal reflux disease in Western patients with non‐ulcer dyspepsia

Review: Eradication of Helicobacter pylori to prevent gastroduodenal diseases: Hitting more than one bird with the same stone

Contact Info

Product

Resources

About